East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more East Resources Acquisition Charts. Click Here for more East Resources Acquisition Charts.](/p.php?pid=staticchart&s=N%5EERES&p=8&t=15)
Growing International Pharmaceutical Company Awards $1 Million
Study to eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services
Award Addresses Significant Late Phase Study for Key Clinical Development
Program
PHILADELPHIA, June 22 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), (NASDAQ:ERES), a leading provider of centralized electrocardiographic
(ECG) collection and interpretation services, announced today that it has been
awarded approximately $1 million in cardiac safety monitoring and services from
a growing international pharmaceutical organization for one of its key drug
candidates in later phase clinical trials.
The award covers an extensive Phase III study, for which eRT will provide
comprehensive support, including provision of 180 units of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards.
"We are pleased that eRT has been selected by the sponsor to provide cardiac
safety services for this critical late phase study on an important compound,"
said Scott Grisanti, senior vice president of business development and chief
marketing officer at eRT. "eRT's ability to marshal and support large volumes
of digital ECG collection equipment for supply to investigative sites was key
to this initiative, which is indicative of the extensive cardiac safety
profiling being incorporated into late phase development programs in response
to emerging regulations and global standards."
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsor may cancel this agreement at its sole discretion. As a
result, actual results may differ materially from any financial outlooks stated
herein. Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission.
DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc., +1-908-203-6473;
or Matt Hayden of Hayden Communications, +1-858-456-4533, for
eResearchTechnology, Inc.
Web site: http://www.ert.com/